{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:00:28Z","timestamp":1791576028652,"version":"4.3.4"},"reference-count":39,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2018,11,8]],"date-time":"2018-11-08T00:00:00Z","timestamp":1541635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R41 CA165626"],"award-info":[{"award-number":["1R41 CA165626"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>We developed a bacterial expression system to produce a recombinant disintegrin, vicrostatin (VCN), whose structure is based on a natural disintegrin isolated from southern copperhead snake venom. Our goal is to develop VCN for potential clinical translation as an anti-cancer agent. VCN is a peptide of 69 amino acids with a single tyrosine residue. We have employed VCN as integrin-targeted radionuclide therapy (brachytherapy) for treatment of glioblastoma (GBM, glioma). GBM is a deadly brain cancer that doesn\u2019t discriminate between sexes and knows no age limit. We established that the tyrosine residue in VCN can be radioiodinated with full retention of bioactivity. 131I-VCN was utilized for integrin-targeted radionuclide therapy using mouse models of glioma. The combination of radioiodinated VCN plus temozolomide (a DNA alkylating agent) significantly prolonged survival of glioma-bearing mice. We also obtained similar results using an immunocompetent mouse model and a murine glioma cell line. In summary, as demonstrated in studies reported here we have shown that VCN as targeted radionuclide therapy for GBM has significant translational potential for therapy of this deadly disease.<\/jats:p>","DOI":"10.3390\/molecules23112918","type":"journal-article","created":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T03:08:02Z","timestamp":1541732882000},"page":"2918","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["A Novel Venom-Derived Peptide for Brachytherapy of Glioblastoma: Preclinical Studies in Mice"],"prefix":"10.3390","volume":"23","author":[{"given":"Steve","family":"Swenson","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Molecular Medicine, University of Southern California, Los Angeles, CA 90089, USA"},{"name":"Department of Neurological Surgery, University of Southern California, Los Angeles, CA 90089, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radu O.","family":"Minea","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of Southern California, Los Angeles, CA 90089, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9129-8241","authenticated-orcid":false,"given":"Cao Duc","family":"Tuan","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Haiphong University of Medicine and Pharmacy, Haiphong, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thu-Zan","family":"Thein","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of Southern California, Los Angeles, CA 90089, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas C.","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of Southern California, Los Angeles, CA 90089, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0880-7901","authenticated-orcid":false,"given":"Francis S.","family":"Markland","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Medicine, University of Southern California, Los Angeles, CA 90089, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,11,8]]},"reference":[{"key":"ref_1","unstructured":"(2018, September 05). Cancer Stat Facts: Brain and Other Nervous System Cancer, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/brain.html."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1159\/000464369","article-title":"Rationale for Aggressive Resection and General Surgical Principles for Intracranial Gliomas","volume":"30","author":"McCutcheon","year":"2018","journal-title":"Prog. Neurol. Surg."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.2147\/TCRM.S135865","article-title":"Dendritic cell vaccines for high-grade gliomas","volume":"14","author":"Eagles","year":"2018","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s00415-017-8695-5","article-title":"Advances in immunotherapeutic research for glioma therapy","volume":"265","author":"Miyauchi","year":"2018","journal-title":"J. Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jocn.2017.10.019","article-title":"How immunotherapies are targeting the glioblastoma immune environment","volume":"47","author":"Felthun","year":"2018","journal-title":"J. Clin. Neurosci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1159\/000464438","article-title":"Surgical Management of Recurrent Intracranial Gliomas","volume":"30","author":"Ferguson","year":"2018","journal-title":"Prog. Neurol. Surg."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1242\/jcs.018556","article-title":"Linking integrin conformation to function","volume":"122","author":"Askari","year":"2009","journal-title":"J. Cell Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0092-8674(92)90115-S","article-title":"Integrins: Versatility, modulation, and signaling in cell adhesion","volume":"69","author":"Hynes","year":"1992","journal-title":"Cell"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/0046-8177(92)90034-Z","article-title":"Integrins and their accessory adhesion molecules in mammary carcinomas: Loss of polarization in poorly differentiated tumors","volume":"23","author":"Pignatelli","year":"1992","journal-title":"Hum. Pathol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0272-2712(18)30514-6","article-title":"Structural and biologic properties of integrin-mediated cell adhesion","volume":"12","author":"Cheresh","year":"1992","journal-title":"Clin. Lab Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/JCI114957","article-title":"Integrins","volume":"87","author":"Ruoslahti","year":"1991","journal-title":"J. Clin. Investig."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"526","DOI":"10.3171\/jns.2005.103.3.0526","article-title":"The role of contortrostatin, a snake venom disintegrin, in the inhibition of tumor progression and prolongation of survival in a rodent glioma model","volume":"103","author":"Pyrko","year":"2005","journal-title":"J. Neurosurg."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1038\/sj.bjc.6601429","article-title":"Irradiation differentially affects substratum-dependent survival, adhesion, and invasion of glioblastoma cell lines","volume":"89","author":"Cordes","year":"2003","journal-title":"Br. J. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15419060302062","article-title":"Functional effect of contortrostatin, a snake venom disintegrin, on human glioma cell invasion in vitro","volume":"10","author":"Schmitmeier","year":"2003","journal-title":"Cell Commun. Adhes."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.2174\/138161211797249189","article-title":"The role of integrins in glioma biology and anti-glioma therapies","volume":"17","author":"Tabatabai","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2174\/1389450033346830","article-title":"Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis","volume":"4","author":"Kumar","year":"2003","journal-title":"Curr. Drug Targets"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1586\/ern.11.188","article-title":"A novel treatment for glioblastoma: Integrin inhibition","volume":"12","author":"Chamberlain","year":"2012","journal-title":"Expert Rev. Neurother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3181\/00379727-195-43129B","article-title":"Disintegrins: A family of integrin inhibitory proteins from viper venoms","volume":"195","author":"Gould","year":"1990","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.2174\/138161207782023793","article-title":"Anti-angiogenesis and RGD-containing snake venom disintegrins","volume":"13","author":"Swenson","year":"2007","journal-title":"Curr. Pharm. Des."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"6617","DOI":"10.2741\/3177","article-title":"Disintegrins in health and disease","volume":"13","author":"McLane","year":"2008","journal-title":"Front. Biosci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"7369","DOI":"10.1021\/bi00244a003","article-title":"Three-dimensional structure of echistatin, the smallest active RGD protein","volume":"30","author":"Saudek","year":"1991","journal-title":"Biochemistry"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1107\/S0907444908002370","article-title":"Structure of acostatin, a dimeric disintegrin from Southern copperhead (Agkistrodon contortrix contortrix), at 1.7 A resolution","volume":"64","author":"Moiseeva","year":"2008","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"21550","DOI":"10.1016\/S0021-9258(20)88220-9","article-title":"Characterization and platelet inhibitory activity of bitistatin, a potent arginine-glycine-aspartic acid-containing peptide from the venom of the viper Bitis arietans","volume":"264","author":"Shebuski","year":"1989","journal-title":"J. Biol. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1161\/01.CIR.83.3.1038","article-title":"Kistrin, a polypeptide platelet GPIIb\/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation","volume":"83","author":"Yasuda","year":"1991","journal-title":"Circulation"},{"key":"ref_26","first-page":"A938","article-title":"Contortrostatin Prevents Reocclusion after Thrombolytic Therapy in a Canine Model of Carotid Artery Thrombosis","volume":"9","author":"Cousins","year":"1995","journal-title":"FASEB J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.toxicon.2011.02.020","article-title":"Development of a chimeric recombinant disintegrin as a cost-effective anti-cancer agent with promising translational potential","volume":"59","author":"Minea","year":"2012","journal-title":"Toxicon"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Minea, R.O., Helchowski, C.M., Zidovetzki, S.J., Costa, F.K., Swenson, S.D., and Markland, F.S. (2010). Vicrostatin\u2014An anti-invasive multi-integrin targeting chimeric disintegrin with tumor anti-angiogenic and pro-apoptotic activities. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0010929"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1042\/bj0890114","article-title":"The Preparation of I-131-Labelled Human Growth Hormone of High Specific Radioactivity","volume":"89","author":"Greenwood","year":"1963","journal-title":"Biochem. J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.critrevonc.2017.01.018","article-title":"Effectiveness of antiangiogenic drugs in glioblastoma patients: A systematic review and meta-analysis of randomized clinical trials","volume":"111","author":"Lombardi","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000467114","article-title":"Brachytherapy of Intracranial Gliomas","volume":"31","author":"Nachbichler","year":"2018","journal-title":"Prog. Neurol. Surg."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/978-3-319-12048-5_4","article-title":"Radiation therapy of glioblastoma","volume":"163","author":"Barani","year":"2015","journal-title":"Cancer Treat. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10143-016-0727-6","article-title":"The role of brachytherapy in the treatment of glioblastoma multiforme","volume":"40","author":"Barbarite","year":"2017","journal-title":"Neurosurg. Rev."},{"key":"ref_34","first-page":"4213","article-title":"Integrin inhibitor cilengitide for the treatment of glioblastoma: A brief overview of current clinical results","volume":"32","author":"Scaringi","year":"2012","journal-title":"Anticancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1042\/BJ20081403","article-title":"Structural requirements of KTS-disintegrins for inhibition of alpha(1)beta(1) integrin","volume":"417","author":"Brown","year":"2009","journal-title":"Biochem. J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood.V90.4.1565","article-title":"Significance of RGD loop and C-terminal domain of echistatin for recognition of alphaIIb beta3 and alpha(v) beta3 integrins and expression of ligand-induced binding site","volume":"90","author":"Marcinkiewicz","year":"1997","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Chang, Y.T., Shiu, J.H., Huang, C.H., Chen, Y.C., Chen, C.Y., Chang, Y.S., and Chuang, W.J. (2017). Effects of the RGD loop and C-terminus of rhodostomin on regulating integrin alphaIIbbeta3 recognition. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0175321"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"6301","DOI":"10.1021\/jm5000547","article-title":"Strategies to inhibit tumor associated integrin receptors: Rationale for dual and multi-antagonists","volume":"57","author":"Sheldrake","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1006\/abbi.2000.2129","article-title":"Chimeric derivative of fibrolase, a fibrinolytic enzyme from southern copperhead venom, possesses inhibitory activity on platelet aggregation","volume":"384","author":"Swenson","year":"2000","journal-title":"Arch. Biochem. Biophys."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/23\/11\/2918\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:28:43Z","timestamp":1760196523000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/23\/11\/2918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,8]]},"references-count":39,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2018,11]]}},"alternative-id":["molecules23112918"],"URL":"https:\/\/doi.org\/10.3390\/molecules23112918","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,8]]}}}